Lexeo director granted 35,000 stock options

Lexeo Therapeutics director Tolga Tanguler received a new stock option award.

Rhea-AI Filing Summary

Lexeo Therapeutics director Tolga Tanguler received a new stock option award. The grant covers 35,000 options to buy Lexeo common stock at an exercise price of $4.70 per share and will expire on June 24, 2036.

According to the vesting terms, 100% of the shares underlying the option will vest, and become exercisable, on the earlier of one year after the grant date or the next annual meeting of stockholders, subject to his continuous service. Following this award, he holds 35,000 stock options directly.

Insider Trade Summary

Grant/Award: 35,000 shares

Grant/Award 1 txn

Insider Tanguler Tolga

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	35,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 35,000 contracts (Direct)

Footnotes (1)

1. F1. 100% of the shares underlying the option shall vest, and become exercisable, on the earlier of one year following the grant date or the next annual meeting of stockholders, subject to the Reporting Person's continuous service on such date.

Key Figures

Options granted: 35,000 options Exercise price: $4.70 per share Options after transaction: 35,000 options +1 more

4 metrics

Options granted 35,000 options Stock Option (right to buy) granted to director on June 25, 2026

Exercise price $4.70 per share Exercise price for the 35,000 Lexeo common shares underlying the options

Options after transaction 35,000 options Total derivative securities held directly by Tanguler following the grant

Expiration date June 24, 2036 Expiration of the granted stock options if not exercised

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, exercise price, vest

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

exercise price financial

"conversion_or_exercise_price: 4.7000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest financial

"100% of the shares underlying the option shall vest, and become exercisable"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Tolga Tanguler acquire in this Lexeo Therapeutics (LXEO) Form 4?

Tolga Tanguler received a grant of 35,000 stock options to buy Lexeo common stock. These options were awarded as compensation and are not an open-market share purchase or sale.

What is the exercise price of Tolga Tanguler’s Lexeo (LXEO) stock options?

The stock options have an exercise price of $4.70 per share. This is the price at which Tanguler can purchase Lexeo common stock once the options vest and become exercisable.

When do Tolga Tanguler’s Lexeo Therapeutics (LXEO) options vest?

All 35,000 options vest on the earlier of one year after the grant date or the next annual meeting of stockholders. Vesting is conditional on Tanguler’s continuous service with the company through that date.

When do Tolga Tanguler’s Lexeo (LXEO) stock options expire?

The options expire on June 24, 2036, giving a long-term window to exercise after vesting. If not exercised by that date, the right to buy Lexeo shares under this grant will lapse.

How many Lexeo (LXEO) derivative securities does Tolga Tanguler hold after this grant?

Following the award, Tanguler holds 35,000 stock options directly. These options each relate to one share of Lexeo common stock and represent his position from this specific grant reported in the Form 4.

Is this Lexeo Therapeutics (LXEO) Form 4 a stock sale or purchase in the market?

No, this Form 4 reports a compensation-related option grant, not a market trade. The transaction is coded as a grant or award acquisition, with no open-market buying or selling of existing shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 04:42 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tanguler Tolga

(Last) (First) (Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, FLOOR 6

(Street)

NEW YORK NEW YORK 10010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.7	06/25/2026		A		35,000		(1)	06/24/2036	Common Stock	35,000	$0	35,000	D

Explanation of Responses:

1. 100% of the shares underlying the option shall vest, and become exercisable, on the earlier of one year following the grant date or the next annual meeting of stockholders, subject to the Reporting Person's continuous service on such date.

	/s/ Youjin Choi, Attorney-in-Fact	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)